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Oral hypoglycemic drugs now
available are of two types. The
biguanides, of which phenformin
(DBI) is the only one available, increase glucose utilization by muscles. The sulfonylureas, tolbutamide
( Orinase), acetohexamide (Dymelor), and chlorpropamide (Diabinese), stimulate the pancreas to
produce and release more insulin.
All three sulfonylureas have the
same effect in responsive patients,
but they differ in potency and in
duration of action.

THE SULFONYLUREAS
Tolbutamide is rapidly metabolized into an inactive chemical that
is promptly excreted in the urine.
Because the blood half-life is six
hours, this drug should be given
two to four times each day. On cessation of treatment the hypoglycemic effect is promptly dissipated.
Acetohexamide has a blood halflife of six hours, but the metabolic
product has hypoglycemic activity
that lasts for several hours before it
is excreted in the urine. In patients
with poor renal function, the metabolite may accumulate in the blood
and cause prolonged hypoglycemia
after a small dose. This drug is usually given twice daily.
Chlorpropamide is not metabolized but is excreted in the urine
over a period of four days. Because
the blood half-life of this drug is 36
hours, the entire daily dose can be
given at breakfast. Since there are
occas~onal reports of cholestatic
jaundice after large doses, chlor.propamide should not be used in
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patients with known or suspected
liver disease.
Comparative studies of these three
drugs shows that chlorpropamide
has the greatest overall effectiveness
with the best diabetic control, the
smallest number of secondary failures, and the lowest cost to the patient. The difference between the
three drugs is so small that each
physician should routinely use only
one but learn to use that one well.
The sulfonylureas are most effective in patients who develop diabetes after the age of 30, who have
few diabetic symptoms, and who
are near normal weight. Younger
patients and those who have ketonuria, weight loss, and the classical
symptoms of diabetes usually require insulin. A few symptomatic
patients who require insulin for initial control may later respond to a
sulfonylurea.
The sulfonylureas are usually of
no value in juvenile patients. On
rare occasions when diabetes was
detected during the asymptomatic
phase, it has been possible to achieve
satisfactory control for several
months with the sulfonylureas. Because this response is always temporary, it is <essential that the patient be followed closely so that
insulin may be started promptly
when needed.
FAILURES OF ORAL
HYPOGLYCEMIC AGENTS

"Primary failure" refers to lack
of response to the oral agent from
the beginning of therapy. "Secondary failure" describes the loss of
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diabetic control after initial satisfactory control for more than a
month on an oral drug. The exact
incidence of secondary failure will
depend upon how freely the drug is
used initially and how strict are the
criteria of control. If the drug is
used only in those patients expected
to have an excellent diabetic response, the incidence of primary
and secondary failure will be low.
If the drug is used in younger patients with moderately severe diabetes, there will be a higher incidence of failures. Some patients
classified as secondary failures initially were not under good control
and should be classified as primary
failures. Many obese patients follow their diet initially, but later eat
excessively, gain weight, develop
hyperglycemia and are classified as
a secondary failure. Some patients
develop poor control during a transient period of stress and must be
changed to insulin. If the sulfonylurea is continued with supplemental insulin during the period of
stress, the oral drug may later be
successful. In our series, the clinic
patients who had a fasting blood
sugar over 200 mg per 100 ml after
being on the maximum dose of the
drug for one week were classified
as secondary failures. The highest
incidence of failure is in the first
few months, but true secondary failure may develop after several years
of excellent diabetic control. A patient who is under excellent control
is less likely to develop secondary
failure than is one who is under
fair control. Patients who required
large doses of insulin have more

secondary failures than do those
who require no insulin. The longer
the duration of diabetes, the greater
is the incidence of secondary failure. The true incidence of secondary failure is probably about 0.25%
during each month of treatment
with a sulfonylurea. The exact rate
makes little difference, as long as
physicians are aware that this condition can occur at any time.

However, sufficient data to substantiate this is not yet available. Patients with minimal diabetes are
more responsive to the sulfonylurea
drugs, and may easily develop hypoglycemia. There is little justification for the use of any drug in patients who have a normal fasting
blood sugar, even though the postprandial blood sugar is elevated.
PHENFORMIN

CONTRAINDICATIONS TO
SULFONYLUREAS

When they were first introduced,
the sulfonylureas were not recommended for patients with infection,
surgery, pregnancy, or neuropathy.
These precautions are still included
on the package inserts. However,
many patients have successfully undergone major surgical procedures
while taking these drugs. Excellent
diabetic control was maintained in
the post-operative period, but a few
patients required supplemental injections of insulin for two or three
days. In the presence of infection,
the insulin requirements rise and
supplemental insulin may be needed
until inflammation has subsided. In
a group of 20 pregnant patients
treated with oral drugs, there was
no evidence of any deleterious effect that could be attributed to the
drugs, even though there were only
13 live babies in the group.
Many physicians have used the
sulfonylurea drugs in patients with
very mild diabetes. Theoretically, if
hypertrophy and hyperplasia of the
,8-cells is produced, the eventual
use of insulin could be postponed.

Phenformin (DBI) is a different
type of chemical that acts on muscle and liver cells in an undetermined manner to increase glucose
uptake. This drug will lower the
blood sugar of any diabetic if a
large enough dose is given, but it
does not lower the blood sugar of
non-diabetics. It is effective in many
patients who do not respond to a
sulfonylurea. It is also used to increase the effectiveness of both sulfonylureas and insulin.
Obese patients taking phenformin
usually lose one pound each month.
Because no other method of treating diabetes causes such consistent
weight loss, this is the preferable
drug for obese diabetics. The average therapeutic dose is slightly less
than 1 mg per lb of body weight,
but there is a narrow therapeutic
margin. If the dose is raised too
high in an effort to produce anorexia, the patient may interpret
nausea as hunger and overeat.
When an excessive dose is given,
any patient will develop such side
effects as metallic taste, foul breath,
anorexia, vomiting, diarrhea, abdominal cramps, and malaise.
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ORAL HYPOGLYCEMIC DRUGS

These side effects are readily controlled by stopping the drug, or
reducing the dose. The incidence of
side effects is less with the use of
the time dispersal (TD) capsules
than it is with the tablets. Severe
side effects are now rare, and true
toxic effects are of little consequence. The tablets have a fourhour duration of action and are
usually given three to four times
daily. The TD capsules have a
longer (12 hours) effect, and are
usually given at breakfast and supper.
There have been reports of lactic
acidosis in patients taking large
doses of phenformin. These patients usually had hepatic, renal, or
severe cardiac disease with shock
and tissue hypoxia. They were seen
only after symptoms of toxicity
had been present for several days.
In our experience lactic acidosis
has not been a problem. It is essential that all diabetic patients be
followed closely regardless of the
method of treatment used.
COMBINED USE OF ORAL
HYPOGLYCEMIC DRUGS

There are some patients who improve but do not attain good control with a sulfonylurea drug with
phenformin alone, but who achieve
satisfactory diabetic control on both
drugs together. The average dose
for the combination is 500 mg of
chlorpropamide and 150 mg of
phenformin each day, but the dose
of either drug must be varied in
order to produce the desired control in each patient.
INSULIN PLUS PHENFORMIN

There have been reports stating
that brittle diabetics can be stabilized if they are given one of the
oral drugs in addition to insulin.
In our study using tolbutamide
with insulin, and then a placebo
with insulin, there was no difference between the two groups. Most ·
diabetics are made unstable by
physicians who prescribe too much
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insulin, resulting in hypoglycemia
and rebound hyperglycemia. When
the insulin dose is reduced, there is
less hypoglycemia and consequently
less rebound hyperglycemia. If the
patient is given another drug at
the same time the insulin dose is
reduced, the new drug is credited
with the improvement actually
produced by the insulin reduction.
Some authors who have reported
good results with this combination
have not used placebo controls.
The combination of insulin plus a
sulfonylurea is worthless, but the
supplemental use of insulin in patients taking a sulfonylurea is helpful during transient stress.
The combination of insulin and
phenformin has been widely advocated to stabilize brittle diabetics.
In our study only 2 out of 37 patients on this regimen showed improvement. The other 35 were no
better controlled than they were on
insulin plus a placebo. The two patients whose control improved possibly ate less because of the mild
anorexia produced by phenformin.
Patients who need insulin usually
do best when they are given nothing
but insulin.
Following the introduction of
oral drugs, the fear was expressed
that the simplified treatment would
result in an epidemic of degenerative complications. This fear has not
been borne out, and as long as satisfactory control is achieved, there
is probably no contraindication to
the use of oral hypoglycemic drugs.
CONCLUSION

The sulfonylurea drugs stimulate
the pancreas to produce more insulin and are effective in patients
with mild diabetes. Because it is
excreted more slowly, chlorpropamide is four times more potent, and
acetohexamide twice as potent, as
tolbutamide. Chlorpropamide gives
the most effective and most economical diabetic control. Phenformin increases the use of glucose
in the muscle cells and is effective
in many patients who do not re-

spond to the sulfonylurea drugs.
The average dose of phenformin is
slightly less than 1 mg per lb body
weight. If excessive phenformin is
given, the patient will develop reversible gastrointestinal side effects.
Phenformin is the only drug associated with consistent weight loss,
and therefore is the drug of choice
in the obese diabetic. Continued use
of phenformin and chlorpropamide
is effective in many patients who
do not achieve satisfactory control
with either drug alone. A combination of sulfonylurea and insulin is
worthless, and a combination of
phenformin and insulin is rarely
valuable. Surgery, pregnancy, infection, or degenerative complications are not absolute contraindica'tions to oral drugs, as long as the
diabetes is well controlled. There
is no evidence of increased incidence of degenerative complications
in patients controlled by oral hypoglycemic drugs.

